---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-25-000017"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:22:25.790902+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SELLAS Q2 net loss $0.07/sh; GPS Phase 3 IDMC positive; SLS009 meets endpoints

## Summary
- IDMC recommends continuing pivotal Phase 3 REGAL trial of GPS in AML without modification; final analysis by year-end 2025.
- Phase 2 SLS009 in r/r AML met all primary endpoints: 44% ORR in AML-MRC; median OS 8.9 months vs 2.4 month historical benchmark.
- FDA recommends advancing SLS009 into first-line AML trial; 80-patient enrollment expected by Q1 2026.
- Q2 2025 net loss $6.6M ($0.07/sh) vs $7.5M ($0.13/sh) in Q2 2024.
- Cash $25.3M at June 30, 2025; additional $4.0M from warrant exercises in July 2025.

## SEC filing metadata
- accession: 0001390478-25-000017
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047825000017/0001390478-25-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047825000017/sls-20250812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-25-000017
- JSON: https://secwatch.observer/filing/0001390478-25-000017.json
- Plain text: https://secwatch.observer/filing/0001390478-25-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.